Taken together, these data demonstrate a requirement for cGMP/PKG pathway activation in PRTG-mediated oncogenic activities and supports PKG inhibition as a viable therapeutic strategy against gastric cancer. The gene discussed is PRTG; the disease is gastric cancer.